Preparation in Materials and Methods) in the apical chamber of a 12 mm diameter (12 well) 109 polyester Transwell chamber with 3 micrometer pore size (Corning, Corning, NY). Before 110 addition of phage and mucin to the apical chamber, the basolateral chamber (i.e. donor 111 compartment) was filled with phosphate buffered saline without calcium and magnesium (PBS, 112 Corning, Corning, NY), as recommended by manufacturer. After 1 hour, peptide-presenting 113
Mucus is an impregnable barrier for drug delivery across the epithelia for treatment of mucosalassociated diseases. While current carriers are promising for mucus penetration, their surface chemistries do not possess chemical complexity to probe and identify optimal physicochemical properties desired for mucus penetration. As initial study, we use M13 phage display presenting random peptides to select peptides that can facilitate permeation through hyperconcentrated mucin. Here, a net-neutral charge, hydrophilic peptide was identified to facilitate transport of phage and fluorophore conjugates through mucin barrier compared to controls. This initial finding warrants further study to understand how composition and spatial distribution of physicochemical properties of peptides can be optimized to improve transport across the mucus barrier.
INTRODUCTION 1
Mucosal surfaces of gastrointestinal, vaginal, respiratory and nasal tissues provide innate 2 protection from pathogens and allow select passage of nutrients during homeostasis (1) (2) (3) . 3
However, in drug delivery across these mucosal-associated tissues and in diseases of the mucus 4 environment such as cystic fibrosis or chronic obstructive pulmonary disease, mucus serves as a 5 physical barrier to prevent drug transport for successful therapy and also creates a local 6 environment to trap and protect pathogens resulting in chronic bacterial infections (1) . Mucus, 7
comprising of mainly mucin glycoprotein (> 95% mucin in all mucus types), is a viscous gel that 8 binds drugs via intermolecular interactions whereby preventing effective penetration. Mucin 9
consists of repeated proline-threonine-serine domains with hydrophilic, glycosylated areas 10 interspaced with hydrophobic globular regions rich in cysteines. As a result, drugs including 11 positively charged tobramycin and gentamicin bind to the net-negatively charged 12 oligosaccharides on mucins, and lipophilic drugs such as progesterone and testosterone interact 13 with hydrophobic domains via van der Waals interactions (4) (5) (6) (7) . Penetration through the mucus 14 barrier would enable effective delivery of drugs towards successful treatment of mucosal-15 associated diseases. Technologies including permeation enhancers (8) , transporter conjugates (9), 16 mucoadhesive polymers (10) , and micro-and nanoparticle systems (11) have been developed to 17 facilitate transport across the mucus, yet it remains a challenge to achieve transmucosal delivery 18 at therapeutic doses. Recent work has shown that hydrophilic, net-neutral formulations improve 19 transport through mucus barriers (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . In particular, particles densely coated with low 20 molecular weight poly(ethylene) glycol (PEG) have demonstrated rapid transport through mucus 21 barriers including cervicovaginal mucus and mucus in pulmonary and gastrointestinal tissues 22 (12-18, 20, 21) . Hydrophilic PEG circumvents binding to the hydrophobic domains on mucus 23 and these formulations possess neutral charge, which avoids electrostatic interactions with 24 negatively charged mucin (20) . While promising, PEG-functionalized formulations have 25 potential challenges including unexpected immunogenicity and hindered cellular internalization 26 and escape, which highlight the need for additional alternatives. Despite their long systemic 27 circulation half-life, PEG formulations have been found to be rapidly cleared after repeated 28 dosing due to the production of anti-PEG antibodies, thereby limiting its use for repeated dosing 29 regimens (22) (23) (24) (25) . PEGylation also has been shown to impair cell internalization and intracellular 30 drug release (26) (27) (28) . DNA polyplexes coated with PEG demonstrated 10-fold reduction in 31 uptake in cell lines compared to non-functionalized polyplexes, and 100 to 1000-fold decrease in 32 release of reporter luciferase gene relative to equivalent naked DNA delivery (26) . PEG is 33 thought to impair the "proton sponge effect" whereby the influx of hydrogen ions into the 34 endosomes and lysosomes causes organelle rupture and allows for drug escape (26, 27) . These 35 challenges of PEGylated formulations present substantial bottlenecks to their long-term success 36 for transmucosal delivery. In addition, formulations functionalized with a single PEG coating 37 will possess uniform surface chemistries, which dictate and limit the number of potential 38 interactions (or lack thereof) to query the complex mucus environment. While mucus is net-39 negative charge and is hydrophilic, there are spatially heterogeneous regions of positive and 40 negative charges and hydrophilic and hydrophobic domains. Mucus acts an "interaction filter" 41 able to form interactions with different substrates (16, 29, 30) . From these observations, it is 42 critical to expand the repertoire of carriers or substrates with greater chemical complexity and 43 diversity of physicochemical properties that achieve unhindered transport through the mucus 44
barrier. 45
Biomolecules such as viruses, proteins, and peptides possess the genetic, chemical, and 46 physical properties for successful transport and transmission through mucosal epithelia. Protein 47 coated viruses (i.e. capsid viruses) have been shown to diffuse through gastric and nasal mucus 48 barriers to effectively bind and infect underlying epithelia. Norwalk virus-like particles (38 nm 49 diameter) and human papilloma virus-like particles (55 nm diameter) transport through healthy 50 mucus as rapidly as in saline (31) . They demonstrated significantly enhanced transport compared 51 with similar-sized (59 nm) synthetic polystyrene nanoparticles, in part due to their complex, 52 dense coating of net-neutral, alternating positive and negatively charged amino acid residues (1, 53 32) . In addition, recent work indicates that molecules with asymmetric charge properties improve 54 transport through hydrogels and mucus, which underscores the importance of the distribution of 55 physicochemical properties on mucus interactions. Li et al. demonstrated that small-sized 56 peptides spatially arranged with a block of positive and then negative charged amino acids 57 (AKAKAKAKAKAEAEAEAEAE) improved transport through mucus than in control saline 58 and diffused better than only positive or all negatively charged peptides (33) . Further, block 59 peptides with same net charge as alternately charged peptides 60 (AKAEAKAEAKAEAKAEAKAE) demonstrated differences in diffusive transport through 61 mucin. Block peptides had different diffusivities in saline and mucin, whereas alternately 62 charged peptides with the same overall charge demonstrated negligible change in transport with 63 or without the presence of mucin. The mucin barrier is able to delineate the local differences in 64 charge distribution from amino acids on the nanometer scale (33) . This finding emphasizes how 65 spatial distribution of amino acids (and their functional groups) can greatly impact transport 66 behavior through the mucus barrier. As a result, substrates with combinations of 67 physicochemical properties can be used to screen and identify optimized, desired functionalities 68 for mucus penetrating delivery. 69
Towards that end, the goal of this work is to use bacteriophage libraries as complex 70 substrates to screen and identify peptides that facilitate transport through mucus barriers. 71
Bacteriophage (phage), or viruses that infect bacteria, have been developed as display systems 72 able to express recombinant peptides or proteins on their viral coat proteins (i.e. capsid proteins). 73
One particular phage, filamentous M13 (Figure 1 ; ~6 nm diameter, 880 nm length) is genetically 74 modifiable such that peptides can be displayed on the various coat proteins of the virus (e.g. p3 75
and p8 as shown in Figure 1 ). By genetically engineering random DNA oligonucleotides 76 encoding peptides into the phage genome, it is feasible to generate phage-presenting random 77 peptide libraries (on a single coat protein) with diversity of up to 10 9 -10 10 different peptides 78 (i.e. different peptide per phage). The phage libraries have peptides with diverse functionalities 79 due to the side chain groups of their amino acids. The libraries are incubated against specific 80 targets such as cells or biomolecules (34) , and by an iterative process of collection, amplification 81 and re-incubation, peptides with affinity for the target are selectively enriched and identified 82 from the library. 83
Using these phage libraries and applying an iterative screening strategy against mucus, 84 peptides can be selected that are muco-inert and mucus-penetrating without a priori knowledge 85 of the heterogeneous mucus composition. Additionally, this approach allows us to screen 86 peptides that transport through mucus irrespective of the heterogeneous microscale rheology of 87 the mucin (35) . The large diversity of random phage-presenting peptides is essentially a 88 collection of formulations with permutations of physicochemical properties. Here, we have 89 identified select peptides that exhibit improved diffusivity in hyperconcentrated mucin compared 90 to controls, and from phage screening, have identified physicochemical properties that are 91 critical for transport across the barrier. This study will serve as the initial step towards 92 elucidating the role of composition towards mucus penetration and importantly, help advance the 93 development of new mucus-penetrating drug delivery systems. 94
MATERIALS AND METHODS 95
Phage Libraries. The Ph.D. 7-mer random peptide phage library (New England Biolabs (NEB), 96
Ipswich, MA) was used to identify peptides that facilitate transport through mucin. The Ph.D. 97 library displays random peptides 7 amino acids in length on the N-terminus of p3 coat protein of 98 M13 bacteriophage. M13 displays peptides encoded by [NNK]7 with a flexible GGGS linker 99 between Acc65I and EagI restriction endonuclease sites, where N = A, C, G, or T and K is G or 100
T to remove two out of three potential stop codons while maximizing sequence diversity. The 101
Ph.D. library was calculated to have diversity of 2*10 9 (i.e. different peptides displayed on each 102 phage), as provided from manufacturer. To visualize phage on agar plates, the M13 vector also 103 contains lacZα gene, where upon bacterial infection with M13 phage, the resulting plaques will 104 appear blue when plated on agar with X-gal substrate. 105
Phage Screening Assay. To use phage libraries in mucin and identify clones able to diffuse 106 through mucin, we developed a phage screening assay (Figure 2 ). 10 11 plaque forming units 107 (pfu)/mL Ph.D. 7-mer phage library were incubated with reconstituted mucin (see Mucin 108
phage that diffused and penetrated through mucin were collected in the donor compartment. To 114 make more copies of collected phage, they were incubated with early log phase XL-1 Blue E. 115 coli (OD600 = 0.2-0.4; Agilent, Santa Clara, CA) in 20 mL Luria-Bertani culture media (LB) for 116 30 minutes non-shaking to allow for infection and then grown for 3 hours at 37°C and 225 rpm 117 for amplification (MaxQ 4000, ThermoFisher Scientific, Hannover Park, IL). After, the culture 118 was centrifuged at 10,000 rpm for 15 min (Sorvall Legend XFR, Newtown, CT) to separate XL-119 1 e. coli from phage in the supernatant. Following standard techniques, phage were then 120 precipitated overnight at 4°C with 1/6 volume poly(ethyelene) glycol 8000 with 2.5 M sodium 121 chloride (PEG 8000/2.5 M NaCl) (Fisher BioReagents, Pittsburgh, PA) (36) . Samples were 122 centrifuged at 10,000 rpm for 15 min and the resulting phage pellet was resuspended in 1 mL 123 PBS. To remove residual bacteria and debris, samples were recentrifuged at 13,000 rpm for 2 124 minutes using a ThermoScientific Legend Microcentrifuge (Hannover Park, IL). Phage 125 supernatant were transferred to a fresh microcentrifuge tube and as a final purification step, 126 samples were then re-precipitated with 1/6 volume PEG 8000/2.5 M NaCl and stored on ice for 1 127 h. Samples were then centrifuged at 10,000 rpm for 15 minutes, and the purified phage pellet 128 was resuspended in 200 µL PBS. Adapting from the protocol by NEB, phage were quantified by 129 titration, i.e. phage activity counted by formation of plaques. Briefly, serial ten-fold dilutions of 130 amplified phage were prepared, and 10 µL from serial dilutions were incubated each with 200 131 µL mid-log XL-1 (OD600 = 0.5-0.8) for 1-5 minutes to allow sufficient time for infection, mixed Mucin Preparation. Type II mucin (Sigma Aldrich, Saint Louis, MO) was used for 145 reconstitution of mucin. As a simple model, 8% mucin preparation (w/w) was used to 146 recapitulate high concentrations observed in cystic fibrosis patients (37, 38) . Lyophilized mucin 147 was reconstituted in PBS at pH= 7.2 following a protocol from McGill and Smyth (39) . 148
In silico analysis of physicochemical properties. The net charge at pH = 7 of sequences was 149 calculated using Protein Calculator v3.4 (Scripps Research Institute, La Jolla, CA). GRAVY 150 (grand average of hydropathy) was calculated according to using 151 www.gravy-calculator.de. 152
Validation Transport Assays. To validate clones could facilitate improved transport, transport 153 was compared between selected clones with negative control M13 that does not display any 154 recombinant peptide on p3 (designated as "wild-type"). Adapting from the transwell assay 155 described earlier, 1*10 10 pfu of each phage was incubated in separate transwells with 8% mucin 156 and incubated for 1 h in the apical chamber. After, the donor compartment was collected (1. including D-glucose and both lytic and filamentous phage similar to M13 in mimics of mucus 174 gels and biofilms (41, 43) . 
RESULTS 178
Enrichment of Phage with Screening Through Mucin. The goal was to establish an assay that 179 allows for screening of phage-based formulations and identify peptides that allow phage 180 transport through a model of reconstituted mucin hydrogel. By setting up the assay that allowed 181
for multiple rounds of screening through mucin, we can reduce the number of phage peptides 182 that penetrate through the mucin barrier. The hyperconcentrated mucin effectively serves as a 183 barrier for phage that penetrate. After the initial round of screening, phage that penetrate through 184 are collected and amplified. By repeating this process for several rounds, phage that 185 nonspecifically diffused due to the heterogeneous pore size of mucin hydrogels can be removed 186 in the additional rounds of screening. Additionally, in each round of screening it is expected that 187 reconstituted mucin would have different microscale viscosity as suggested/demonstrated by 188 others (35) ; as a result, by subjecting the libraries to repeated screening, phage that penetrate 189 mucin irrespective of the heterogeneity of the composition or pore size would be discovered. 190
This strategy is relevant to human pathology, where there is patient to patient variability in 191 mucus concentration and composition, as often seen in patients with cystic fibrosis or chronic 192 obstructive pulmonary disease (1) . For each round of screening, or panning, we incubated 1*10 11 193 plaque forming units (i.e. number of infective phage) in freshly prepared 8% mucin and collected 194 the eluates that penetrated after 1 h. We amplified phage eluates to make more copies of the 195 resulting sub-library and iterated this experiment for three additional rounds. To validate 196 enrichment, equivalent amounts of collected phage that were amplified from each round were 197 incubated with mucin and penetrating phage were collected and titered. There is an approximate 198 three-fold improvement, or enrichment in collected phage from phage pool in round three 199 compared with earlier rounds (Figure 3) . 200
Identification of Sequences and Their Physicochemical Properties. To identify potential 201
penetrating phage clones, we isolated individual phage after three rounds of screening against 202 mucin. After the third round of screening, penetrating phage were plated on agar, and individual 203 plaques representing individual clones were grown with E. coli in culture, and the DNA of the 204 individual clones were isolated. Since the DNA sequence of the M13 vector links with the 205 phenotype, the DNA sequence fused with gene 3 encodes for the peptide displayed on N-206 terminus of p3 coat protein. After DNA sequencing of 13 clones, we found that two sequences, 207 showed up repeatedly, with sequence TVRTSAD having a frequency of 4/13 clones and 208 NTGSPYE having a frequency of 1/13 ( Table 1) . These sequences have an approximate net 209 charge of 0 (-0.1) and -1 (-1.1), respectively ( Table 1 ). In addition, these peptides are 210 hydrophilic, as indicated by the negative GRAVY scores calculated from the Kyte-Doolittle 211 hydropathy plot (Table 1)(40, 44) . The negative values, which represent the average score of the 212 amino acid at that position relative to surrounding amino acids (i.e. window range), reflects the 213 overall hydrophilic property of the sequence. Also from sequencing, there were clones without 214 insert (wild-type) and sequences with deletions and frame shifts in the randomized 7mer 215 sequence. Since TVRTSAD sequence was most abundant, subsequent experiments were done 216 using this clone. 217
Enhanced Transport and Diffusivity of Selected Phage and Peptide Clones. To confirm that 218
identified peptides present on M13 have minimal mucin binding to permit mucin penetration, we 219 tested their transport through mucin compared with negative control wild-type M13. Similar to 220 the screening assay, we incubated equivalent amounts of selected clones and wild type in 221 separate transwells with mucin, collected fractions in the donor compartment, and quantified the 222 fractions by titering. As seen in Figure 4A after 1 h incubation, significantly more TVRTSAD-223 presenting phage transports through mucin compared with wild-type, suggesting that the peptide 224 improves transport. 225
After validating improved transport with selected phage, we quantified the diffusive 226 behavior of phage in mucin. Previously, the diffusive behavior of lytic and lysogenic filamentous 227 bacteriophage had been quantified through gels and artificial biofilms to determine their 228 feasibility as natural antimicrobial therapeutics to penetrate and effectively diffuse and bind to 229 these complex ecosystems (43) . Adapting that method, we quantified diffusivity of our clones 230 compared to controls. In four separate transwells designated for 15, 30, 45, and 60 min of 231 diffusion, either TVRTSAD or wild-type control at equal starting concentrations were incubated 232 for the given timepoint. After each timepoint, samples were collected in the donor compartment 233 and the concentrations were determined by titering. From the amount Q (in plaque forming 234 units), we calculated the apparent diffusivity, or Dapp, of the phage. TVRTSAD-phage has an 235 apparent diffusivity of 2.81*10 -9 cm 2 /s, which is approximately over two-fold greater than wild-236 type control with 1.33*10 -9 cm 2 /s (Figure 4) . 237
Next, we wanted to take the peptides out of the structural context of phage and confirm 238 that the selected peptides facilitate diffusion of molecular conjugates in mucin. Synthetized 239 peptides conjugated with fluorescein isothiocyanate (FITC) were incubated in PBS and mucus 240 and their bulk diffusion was measured; from these experiments, their diffusion coefficients were 241 calculated. The graphs representing amount of solute Q transferred versus time in saline and 242 mucus are shown in Figure 5A -C (here, solutes are FITC-peptides and the control fluorescein 243 sodium salt). The amount of solute transferred increased with time. As indicated from the graphs 244 for all solutes, there is a linear relationship between Q and time, and therefore application of 245 Equation 1 is valid for the duration of the experiment. From these measurements, we can 246 calculate their diffusion coefficients. Here, FITC-labeled TVRTSAD had an approximate 247 diffusivity of 5.10*10 -8 and 0.94*10 -8 cm 2 /s in PBS and mucin, respectively (Figure 5) . While 248 the values are comparable to fluorescein sodium salt in PBS, there is two-fold less diffusion in 249 mucin. Interestingly, the selected TVRTSAD peptide demonstrated improved diffusivity than 250 negative control hepta-arginine (R7; +7 net charge) in mucin (Figure 5D; Table 2 ). Table 2 lists 251 the calculated diffusivities of FITC-peptides and fluorescein salt in mucus and saline. Mucin 252 hinders the diffusion of FITC-peptides and control fluorescein salt. Diffusion coefficients in 253 mucus were decreased almost six-fold compared to PBS (Table 2) , which are consistent with 254 prior work where solutes with various molecular weights and physicochemical properties 255 presented similar range of decreased diffusivities in porcine gastric mucus (45) . Peptide 256 conjugates demonstrate less effective diffusivity (DPBS/Dmucin) than fluorescein salt but greater 257 effective diffusivity than control peptide R7. TVRTSAD had less than two-fold decrease in 258 diffusion than fluorescein sodium salt in mucin, in spite of being four times large (in molecular 259 weight; Table 2 ). 260
261

DISCUSSION 262
For each successive round of panning, there is an increase in the amount of phage 263 diffusing through the mucin barrier, which suggests that there is enrichment for mucin-264 penetrating phage (Figure 3) . As expected, there is no significant difference of phage going 265 through from pools collected from rounds 1 and 2. This finding is expected, as in the first two 266 rounds in panning against other molecules, including proteins, cells or tissues, conventional 267 panning results in minimal enrichment until at least round three (46) . Enrichment is most likely 268 due to the reasoning that after several rounds, non-specific clones were trapped by the mucin gel 269 and with multiple rounds of amplification, more copies of penetrating phage clones were 270 produced and applied in subsequent rounds of screening. While additional rounds of panning 271 could result in further enrichment, it is important to minimize the presence of false positives or 272 parasitic sequences, i.e. phage that amplify rapidly and do not contribute to improved transport, 273 such as wild-type phage (47) . Even after three rounds, there is the presence of wild-type, 274 insertless phage, along with other mutant sequences ( Table 1) . Consequently, after three rounds 275 of screening, we proceeded to identify and validate individual clones for enhanced transport. 276
From in silico analysis, we identified the physicochemical properties of select peptides 277 from library panning. The most abundant peptide sequence, TVRTSAD, was neutral and 278 hydrophilic. This result may be expected since mucin is negatively charged due to the sulfuric 279 acid and sulfate content and has exposed hydrophobic domains (1), it is anticipated that phage 280 peptides that penetrate through mucin are hydrophilic and will have minimal positively charged 281 residues (33) . These properties are similar to net neutral, hydrophilic PEG-coated particles used 282 for transmucosal delivery (13, 15, 21) . 283
To confirm that identified peptides present on M13 have minimal mucin binding and 284
achieve mucin penetration, we tested their transport through mucin compared with negative 285 control wild-type M13. Here, clone TVRTSAD transports through mucin compared with wild-286 type, suggesting that the peptide improves transport. Except for the peptide sequence displayed 287 on the N-terminus of p3 of TVRTSAD, both TVRTSAD and wild-type phage are genetically 288 and phenotypically indistinguishable with identical coat proteins, which suggest that the peptide 289 is primarily responsible for enhanced transport. The primary sequence of the peptide and the 290 Kyte-Doolittle hydropathy plot suggest that the hydrophilic character of peptide may reduce 291 phage adhesion to the hydrophobic domains of mucin and permit the phage to diffuse more 292 rapidly. Using the method developed by Hu et al., we quantified the diffusive behavior of phage 293 in mucin. TVRTSAD has an apparent diffusivity of 2.81*10 -9 cm 2 /s, which is approximately 294 over two-fold more than wild-type control.
While these experiments were done in 295 hyperconcentrated 8% mucin, the apparent diffusivities are the same order of magnitude as 296 observed with diffusion of similarly structured filamentous fNEL phage through 1% agarose 297 with and without E. coli (41, 43) . fNEL exhibited apparent diffusivity of 2.6*10 -9 cm 2 /s and 298 6.8*10 -8 cm 2 /s through 1% and 0% agarose, respectively (41) . The filamentous morphology 299 decreased apparent diffusion of fNEL compared with icosahedral T4; It is hypothesized that the 300 filamentous structure of fNEL more easily aggregates and gets trapped compared to smaller T4 301 (41) . While selected phage demonstrates significant yet modest increase in diffusivity compared 302 to negative control and is comparable to other filamentous phage diffusing through less 303 concentrated agarose barriers, the diffusivity is less than observed with smaller icosahedral T4 or 304 other PEG-coated particles (13, 41) . While these effects to slow diffusivity are feasible, M13 is a 305 flexible rod (48) able to take multiple conformations. M13 has a radius of gyration of ~140 nm 306 (49) , which is less than its length (~880 nm) yet greater than its diameter (~6-7 nm). The 307 flexibility and ability to take multiple conformations potentially allows for peptide to reduce 308 interaction with mucin to help facilitate transport. 309
Finally, we wanted to confirm that selected peptides were functional without display on 310 the phage and could facilitate transport of small molecules as conjugates through the mucin 311 barrier. FITC-labeled peptides were incubated in mucin and control saline to determine hindered 312 and unhindered diffusion, respectively. All peptide conjugates and fluorescein salt exhibited 313 decreased diffusion in mucin compared to saline. Fluorescein salt had 3-fold decreased diffusion, 314
whereas peptide conjugates had approximately 4-to 5-fold reduced diffusivity. This suggests 315 mucin, regardless or pore size, interacts and filters away small molecules through intermolecular 316 interactions, as seen in previous studies with other small molecule drugs (50) . Interestingly, the 317 selected peptides demonstrated better effective diffusivity (DPBS/Dmucus) than control cell-318 penetrating peptide hepta-arginine, which has hindered diffusion in mucus most likely due to 319 charge interactions with net-negative charge mucin. This suggests that the amino acid 320 composition can impact transport. Others have demonstrated that differences in amino acid 321 sequence and composition can impact transport through mucin (16, 33) . Li et al. demonstrated 322 that net neutral charged peptides demonstrated improved transport compared to net positive and 323 negative charged peptides; by altering the sequence of positive and negative charges could also 324 impact the binding and penetration through the mucin barrier (33) . 325
CONCLUSIONS 326
We have developed a high-throughput screening assay using phage display libraries to 327 identify peptides that reduce phage-mucin interactions and improve diffusivity of phage through 328 hyperconcentrated mucin. Phage libraries provide a large collection of peptides with diverse 329 chemistries (~10 9 diversity) from which we can screen peptides that exhibit mucus-penetrating or 330 muco-inert properties and may serve as a potential "coating" for drug delivery systems to 331 improve transport through mucus barriers. From these initial screens, validated peptides were 332 neutral to slightly negatively charged and are hydrophilic. Interestingly, these findings are 333 consistent with previous work using low molecular weight, densely coated PEG nanoparticles as 334 muco-inert particles for mucus penetration in multiple tissues (12, 13, 18, 20) . While this study 335 focused on high concentration of reconstituted mucin, future studies will require the use of more 336 relevant concentrations and composition of mucus present in tissues and in diseases to truly 337 recapitulate the (patho)physiology to understand and achieve mucus penetration (1, 15, 29, 30, 338 35) . The selected phage clone exhibited improved diffusivity through high percentage mucin 339 compared to control. To improve diffusivity, peptides could be engineered onto the p8 coat of 340 M13, which has 2700 copies for more multivalent display and surface area to probe interactions 341 with mucus. Alternatively, due to the "bulky" length of the filamentous M13 (~880 nm), further 342 work to improve diffusivity could involve engineering peptides onto smaller viruses or 343 functionalize onto polymeric 100 and 200 nm nanoparticles traditionally used in mucus 344 penetrating delivery (13, (17) (18) (19) . Out of the context of phage, the select peptides improved 345 diffusivity compared to control positively charged peptides. However, they did not necessarily 346 improve diffusion compared to fluorescein salt but possessed a higher molecular weight. Using 347 next-generation sequencing, it may be possible to identify from a larger population of sequences 348 additional peptides that may offer even further improvement on diffusivity (51, 52) . While we 349 identified a few peptides that did not share sequence homology with each other, with additional 350 rounds of panning and sequence analysis we can begin to identify convergent peptide motifs that 351 may be responsible for conferring optimal muco-inert properties. Through selective, systematic 352 mutagenesis of amino acids of these peptides, it may be possible to dissect which amino acids 353 (and their functionalities) are responsible for penetration through mucin. While we evaluated 354 diffusivity of peptide conjugates to fluorophores, these muco-inert peptides could be conjugated 355 to small molecule drugs previously impermeable to mucus penetration such as tobramycin and 356 hydrocortisone or serve as potential alternative coatings for mucus penetrating drug delivery 357 systems. From these insights, the promise of mucus-penetrating delivery can be realized. 358 Figure 1 . Cartoon of filamentous M13 bacteriophage with minor coat protein p3 at the proximal end and p8 major coat protein along the length of the bacteriophage.
Figure 2.
Schematic of phage screening assay. A. linear Ph.D. M13 library is incubated with hyperconcentrated mucin in the donating reservoir of receiving chamber. B. during timecourse, select phage diffuse through the mucin barrier into the receiving reservoir (see zoom in center). C. select phage are collected and are split-quantified by titering (i.e. double layer plaque assay) or amplified in E. coli to generate more phage that eluted through mucin. D. Amplified phage are quantified by titering and then the iterative selection, or biopanning, is repeated in the next round. This assay is done in multiple rounds (at least three). 
